DeepMed Research

Caprock Mining Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 102

Market Cap: $155.6M

Website: http://www.capricor.com

Introduction: Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Clinical Trials

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Biological: Allogeneic Cardiosphere-Derived Cells (CAP-1002)

First Posted Date: 2024-03-12

Last Posted Date: 2024-04-24

Lead Sponsor: Capricor Inc.

Target Recruit Count: 8

Registration Number: NCT06304064

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Cincinnati Children's Medical Center, Cincinnati, Ohio, United States

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Phase 3

Active, not recruiting

Conditions: Muscular Dystrophies
Neuromuscular Diseases
Muscular Disorders, Atrophic
Muscular Diseases
Nervous System Diseases
Muscular Dystrophy, Duchenne
Genetic Diseases, X-Linked
Genetic Diseases, Inborn

Interventions: Biological: Deramiocel (CAP-1002)
Biological: Placebo
Biological: CAP-1002

First Posted Date: 2021-11-19

Last Posted Date: 2025-02-04

Lead Sponsor: Capricor Inc.

Target Recruit Count: 104

Registration Number: NCT05126758

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
UCSD Altman Clinical and Translational Research Institute, La Jolla, California, United States

and more 18 locations

Intravenous Infusion of CAP-1002 in Patients With COVID-19

Phase 2

Completed

Conditions: Covid19

Interventions: Biological: Placebo
Biological: CAP-1002

First Posted Date: 2020-11-10

Last Posted Date: 2025-02-20

Lead Sponsor: Capricor Inc.

Target Recruit Count: 55

Registration Number: NCT04623671

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California Davis, Sacramento, California, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 1 locations

Open-label Extension of the HOPE-2 Trial

Phase 2

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Biological: Deramiocel (CAP-1002)

First Posted Date: 2020-06-11

Last Posted Date: 2025-02-24

Lead Sponsor: Capricor Inc.

Target Recruit Count: 13

Registration Number: NCT04428476

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 2 locations

CAP-1002 in Severe COVID-19 Disease

Conditions: COVID-19

First Posted Date: 2020-04-08

Last Posted Date: 2020-12-01

Lead Sponsor: Capricor Inc.

Registration Number: NCT04338347

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Phase 2

Completed

Conditions: Muscular Dystrophies
Genetic Diseases, Inborn
Muscular Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Muscular Dystrophy, Duchenne
Neuromuscular Diseases
Muscular Disorders, Atrophic

Interventions: Drug: Placebo
Biological: CAP-1002

First Posted Date: 2018-01-23

Last Posted Date: 2025-02-24

Lead Sponsor: Capricor Inc.

Target Recruit Count: 20

Registration Number: NCT03406780

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States

and more 6 locations

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

Phase 1

Completed

Conditions: Heart Failure
Renal Insufficiency

Interventions: Drug: Cenderitide
Drug: Placebo

First Posted Date: 2015-11-13

Last Posted Date: 2020-02-11

Lead Sponsor: Capricor Inc.

Target Recruit Count: 8

Registration Number: NCT02603614

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy
Cardiomyopathy

Interventions: Drug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)

First Posted Date: 2015-06-30

Last Posted Date: 2025-01-09

Lead Sponsor: Capricor Inc.

Target Recruit Count: 25

Registration Number: NCT02485938

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

Safety Study of Cenderitide in Stable Chronic Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Cenderitide

First Posted Date: 2015-02-09

Last Posted Date: 2020-02-11

Lead Sponsor: Capricor Inc.

Target Recruit Count: 14

Registration Number: NCT02359227

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

Phase 1

Conditions: Nonischemic Cardiomyopathy
Ischemic Cardiomyopathy
Heart Failure
Dilated Cardiomyopathy (DCM)

Interventions: Biological: Allogeneic Cardiosphere-Derived Cells (CDCs)

First Posted Date: 2014-11-18

Last Posted Date: 2016-06-21

Lead Sponsor: Capricor Inc.

Target Recruit Count: 42

Registration Number: NCT02293603

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy